https://orcid.org/0000-0002-5834-4063
References
- Santoro A, Franceschini E, Meschiari M, et al. Epidemiology and risk factors associated with mortality in consecutive patients with bacterial bloodstream infection: impact of MDR and XDR bacteria. Open Forum Infect Dis. 2020;7(11):ofaa461. DOI: 10.1093/ofid/ofaa461.
- Martin-Loeches I, Garduno A, Povoa P, et al. Choosing antibiotic therapy for severe community-acquired pneumonia. Curr Opin Infect Dis. 2022;35:133–139.
- Pogue JM, Kaye KS, Cohen DA, et al. Appropriate antimicrobial therapy in the era of multidrug-resistant human pathogens. Clin Microbiol Infect. 2015;21(4):302–312.
- Macdonald M. Patient safety. Clinic Nurs Special. 2010;24:196–201.
- Coopersmith CM, de Backer D, Deutschman CS, et al. Surviving sepsis campaign: research priorities for sepsis and septic shock. Intensive Care Med. [Internet]. 2018;44:1400–1426. Available from: http://link.springer.com/10.1007/s00134-018-5175-z
- Roberts JA, Abdul-Aziz MH, Lipman J, et al. Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions. Lancet Infect Dis. [Internet]. 2014;14:498–509. Available from: https://linkinghub.elsevier.com/retrieve/pii/S1473309914700362
- de Waele JJ, Carrette S, Carlier M, et al. Therapeutic drug monitoring-based dose optimisation of piperacillin and meropenem: a randomised controlled trial. Intensive Care Med. [Internet]. 2014;40:380–387. Available from: http://link.springer.com/10.1007/s00134-013-3187-2
- Wong G, Brinkman A, Benefield RJ, et al. An international, multicentre survey of -lactam antibiotic therapeutic drug monitoring practice in intensive care units. J Antimicrob Chemother. [Internet]. 2014;69:1416–1423. Available from: https://academic.oup.com/jac/article-lookup/do/10.1093/jac/dkt523
- Caro YS, Cámara MS, de Zan MM. A review of bioanalytical methods for the therapeutic drug monitoring of β-lactam antibiotics in critically ill patients: evaluation of the approaches used to develop and validate quality attributes. Talanta. [Internet]. 2020;210:120619. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0039914019312524
- Roberts JA, Norris R, Paterson DL, et al. Therapeutic drug monitoring of antimicrobials. Br J Clin Pharmacol. [Internet]. 2012;73:27–36. Available from: https://pubmed.ncbi.nlm.nih.gov/21831196
- Vincent JL, Sakr Y, Singer M, et al. Prevalence and outcomes of infection among patients in intensive care units in 2017. JAMA. [Internet]. 2020 [cited 2020 Jul 2];323:1478–1487. Available from: https://pubmed.ncbi.nlm.nih.gov/32207816/
- Tiszai-Szucs T, Mac Sweeney C, Keaveny J, et al. Feasibility of antimicrobial stewardship (AMS) in critical care settings: a multidisciplinary approach strategy. Med Sci. 2018;6:40.
- Martin-Loeches I, Levy MMMM, Artigas A. Management of severe sepsis: advances, challenges, and current status. Drug Des Devel Ther. [Internet]. 2015;9:2079–2088. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25926718
- Martin-Loeches I, Diaz E, Valles J, et al. Risks for multidrug-resistant pathogens in the ICU. Curr Opin Crit Care. [Internet]. 2014;20:516–524. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25188366
- Jager NGL, van Hest RM, Lipman J, et al. Antibiotic exposure at the site of infection: principles and assessment of tissue penetration. Expert Rev Clin Pharmacol. 2019;12:623–634.